2019 Future of Rosacea R&D Pipeline Drugs and Companies- Analysis of Global Rosacea Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Rosacea treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Rosacea pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Rosacea pipeline companies from advancing their products into Phase 3 or Phase 4.
Rosacea Report Description
The H1 2019 pipeline review report on Rosacea pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Rosacea pipeline compounds.
The Rosacea pipeline guide presents information on all active drugs currently being developed for Rosacea. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Rosacea pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Rosacea drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Rosacea product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Rosacea pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Rosacea pipeline report includes
REASONS TO BUY
Rosacea Report Description
The H1 2019 pipeline review report on Rosacea pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Rosacea pipeline compounds.
The Rosacea pipeline guide presents information on all active drugs currently being developed for Rosacea. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Rosacea pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Rosacea drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Rosacea product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Rosacea pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Rosacea pipeline report includes
- An overview of Rosacea disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of pipeline compounds
- Company wise list of pipeline compounds
- Mechanism of Action wise pipeline compounds
- For each pipeline product, the following details are provided-
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials
REASONS TO BUY
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Rosacea pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Rosacea pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into the market through in-depth strategic analysis review
- Know the list of companies participating in global Rosacea pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL ROSACEA PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Rosacea Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Rosacea pipeline, H1- 2019
3.5 Mechanism of Action wise Rosacea Pipeline Candidates
4. ACCUITIS ROSACEA PIPELINE DETAILS
4.1 Accuitis Business Profile
4.2 Accuitis Rosacea Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. ACCUITIS PHARMACEUTICALS INC ROSACEA PIPELINE DETAILS
5.1 Accuitis Pharmaceuticals Inc Business Profile
5.2 Accuitis Pharmaceuticals Inc Rosacea Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. AFECTA PHARMACEUTICALS INC ROSACEA PIPELINE DETAILS
6.1 Afecta Pharmaceuticals Inc Business Profile
6.2 Afecta Pharmaceuticals Inc Rosacea Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. AOBIOME LLC ROSACEA PIPELINE DETAILS
7.1 AOBiome LLC Business Profile
7.2 AOBiome LLC Rosacea Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. BIOPHARMX INC ROSACEA PIPELINE DETAILS
8.1 BioPharmX Inc Business Profile
8.2 BioPharmX Inc Rosacea Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. CELLIX BIO PVT LTD ROSACEA PIPELINE DETAILS
9.1 Cellix Bio Pvt Ltd Business Profile
9.2 Cellix Bio Pvt Ltd Rosacea Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. CUTANEA LIFE SCIENCES INC ROSACEA PIPELINE DETAILS
10.1 Cutanea Life Sciences Inc Business Profile
10.2 Cutanea Life Sciences Inc Rosacea Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. DERMATA THERAPEUTICS LLC ROSACEA PIPELINE DETAILS
11.1 Dermata Therapeutics LLC Business Profile
11.2 Dermata Therapeutics LLC Rosacea Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. EMERITI PHARMA AB ROSACEA PIPELINE DETAILS
12.1 Emeriti Pharma AB Business Profile
12.2 Emeriti Pharma AB Rosacea Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. FOAMIX PHARMACEUTICALS LTD ROSACEA PIPELINE DETAILS
13.1 Foamix Pharmaceuticals Ltd Business Profile
13.2 Foamix Pharmaceuticals Ltd Rosacea Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. HOVIONE ROSACEA PIPELINE DETAILS
14.1 Hovione Business Profile
14.2 Hovione Rosacea Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15. MATRISYS BIOSCIENCE INC ROSACEA PIPELINE DETAILS
15.1 Matrisys Bioscience Inc Business Profile
15.2 Matrisys Bioscience Inc Rosacea Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16. PHI THERAPEUTICS INC ROSACEA PIPELINE DETAILS
16.1 PHI Therapeutics Inc Business Profile
16.2 PHI Therapeutics Inc Rosacea Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17. PROMIUS PHARMA LLC ROSACEA PIPELINE DETAILS
17.1 Promius Pharma LLC Business Profile
17.2 Promius Pharma LLC Rosacea Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18. SOL-GEL TECHNOLOGIES LTD ROSACEA PIPELINE DETAILS
18.1 Sol-Gel Technologies Ltd Business Profile
18.2 Sol-Gel Technologies Ltd Rosacea Drug Details
18.2.1 Drug Snapshot
18.2.1.1 Originator
18.2.1.2 Collaborator/Co-Developer
18.2.1.3 Route of Administration
18.2.1.4 Orphan Drug/Fast Track/Special Designation
18.2.1.5 Area
18.2.1.6 Type of Molecular Entity
18.3 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19. SUNNY PHARMTECH INC ROSACEA PIPELINE DETAILS
19.1 Sunny Pharmtech Inc Business Profile
19.2 Sunny Pharmtech Inc Rosacea Drug Details
19.2.1 Drug Snapshot
19.2.1.1 Originator
19.2.1.2 Collaborator/Co-Developer
19.2.1.3 Route of Administration
19.2.1.4 Orphan Drug/Fast Track/Special Designation
19.2.1.5 Area
19.2.1.6 Type of Molecular Entity
19.3 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments
20. TWI BIOTECHNOLOGY INC ROSACEA PIPELINE DETAILS
20.1 TWi Biotechnology Inc Business Profile
20.2 TWi Biotechnology Inc Rosacea Drug Details
20.2.1 Drug Snapshot
20.2.1.1 Originator
20.2.1.2 Collaborator/Co-Developer
20.2.1.3 Route of Administration
20.2.1.4 Orphan Drug/Fast Track/Special Designation
20.2.1.5 Area
20.2.1.6 Type of Molecular Entity
20.3 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments
20. LATEST ROSACEA DRUG PIPELINE DEVELOPMENTS, 2019
21. APPENDIX
21.1 About Us
21.2 Sources and Methodology
21.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL ROSACEA PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Rosacea Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Rosacea pipeline, H1- 2019
3.5 Mechanism of Action wise Rosacea Pipeline Candidates
4. ACCUITIS ROSACEA PIPELINE DETAILS
4.1 Accuitis Business Profile
4.2 Accuitis Rosacea Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. ACCUITIS PHARMACEUTICALS INC ROSACEA PIPELINE DETAILS
5.1 Accuitis Pharmaceuticals Inc Business Profile
5.2 Accuitis Pharmaceuticals Inc Rosacea Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. AFECTA PHARMACEUTICALS INC ROSACEA PIPELINE DETAILS
6.1 Afecta Pharmaceuticals Inc Business Profile
6.2 Afecta Pharmaceuticals Inc Rosacea Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. AOBIOME LLC ROSACEA PIPELINE DETAILS
7.1 AOBiome LLC Business Profile
7.2 AOBiome LLC Rosacea Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. BIOPHARMX INC ROSACEA PIPELINE DETAILS
8.1 BioPharmX Inc Business Profile
8.2 BioPharmX Inc Rosacea Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. CELLIX BIO PVT LTD ROSACEA PIPELINE DETAILS
9.1 Cellix Bio Pvt Ltd Business Profile
9.2 Cellix Bio Pvt Ltd Rosacea Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. CUTANEA LIFE SCIENCES INC ROSACEA PIPELINE DETAILS
10.1 Cutanea Life Sciences Inc Business Profile
10.2 Cutanea Life Sciences Inc Rosacea Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. DERMATA THERAPEUTICS LLC ROSACEA PIPELINE DETAILS
11.1 Dermata Therapeutics LLC Business Profile
11.2 Dermata Therapeutics LLC Rosacea Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. EMERITI PHARMA AB ROSACEA PIPELINE DETAILS
12.1 Emeriti Pharma AB Business Profile
12.2 Emeriti Pharma AB Rosacea Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. FOAMIX PHARMACEUTICALS LTD ROSACEA PIPELINE DETAILS
13.1 Foamix Pharmaceuticals Ltd Business Profile
13.2 Foamix Pharmaceuticals Ltd Rosacea Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. HOVIONE ROSACEA PIPELINE DETAILS
14.1 Hovione Business Profile
14.2 Hovione Rosacea Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15. MATRISYS BIOSCIENCE INC ROSACEA PIPELINE DETAILS
15.1 Matrisys Bioscience Inc Business Profile
15.2 Matrisys Bioscience Inc Rosacea Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16. PHI THERAPEUTICS INC ROSACEA PIPELINE DETAILS
16.1 PHI Therapeutics Inc Business Profile
16.2 PHI Therapeutics Inc Rosacea Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17. PROMIUS PHARMA LLC ROSACEA PIPELINE DETAILS
17.1 Promius Pharma LLC Business Profile
17.2 Promius Pharma LLC Rosacea Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18. SOL-GEL TECHNOLOGIES LTD ROSACEA PIPELINE DETAILS
18.1 Sol-Gel Technologies Ltd Business Profile
18.2 Sol-Gel Technologies Ltd Rosacea Drug Details
18.2.1 Drug Snapshot
18.2.1.1 Originator
18.2.1.2 Collaborator/Co-Developer
18.2.1.3 Route of Administration
18.2.1.4 Orphan Drug/Fast Track/Special Designation
18.2.1.5 Area
18.2.1.6 Type of Molecular Entity
18.3 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19. SUNNY PHARMTECH INC ROSACEA PIPELINE DETAILS
19.1 Sunny Pharmtech Inc Business Profile
19.2 Sunny Pharmtech Inc Rosacea Drug Details
19.2.1 Drug Snapshot
19.2.1.1 Originator
19.2.1.2 Collaborator/Co-Developer
19.2.1.3 Route of Administration
19.2.1.4 Orphan Drug/Fast Track/Special Designation
19.2.1.5 Area
19.2.1.6 Type of Molecular Entity
19.3 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments
20. TWI BIOTECHNOLOGY INC ROSACEA PIPELINE DETAILS
20.1 TWi Biotechnology Inc Business Profile
20.2 TWi Biotechnology Inc Rosacea Drug Details
20.2.1 Drug Snapshot
20.2.1.1 Originator
20.2.1.2 Collaborator/Co-Developer
20.2.1.3 Route of Administration
20.2.1.4 Orphan Drug/Fast Track/Special Designation
20.2.1.5 Area
20.2.1.6 Type of Molecular Entity
20.3 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments
20. LATEST ROSACEA DRUG PIPELINE DEVELOPMENTS, 2019
21. APPENDIX
21.1 About Us
21.2 Sources and Methodology
21.3 Contact Information
